Subgroup analysis of randomized clinical trials appears to indicate that abciximab provides substantial benefits in terms of reduced repeat revasculariza-tion and mortality among diabetic patients, with comparable effects observed with tirofiban. Clinical trial evidence with bivalirudin supports similar con clusions. In the REPLACE-2 study of bivalirudin and provisional GP IIb/IIIa inhibition compared with heparin and GP IIb/IIIa inhibition, bivalirudin-treated diabetic patients experienced a lower, but nonsignificant rate of mortality at 12 months (2.3% versus 3.9%, P = NS). No difference in the rate of 30-day bleeding and ischemic outcomes was observed.57 Although the long-term effects of enoxaparin-based strategies in diabetic patients have not been reported, a substantial rate of concomitant GP IIb/IIIa use in these studies will limit the interpretation of these data.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment